Please login to the form below

Not currently logged in
Email:
Password:

Novartis forms strategic partnership with Lonza

Novartis has formed a new strategic partnership with biotech company, Lonza
Novartis has formed a new strategic partnership with biotech company, Lonza, which specialises in process development and manufacturing. It is hoped the partnership will rapidly scale-up technical development and clinical production for part of the Novartis biologics pipeline.

Novartis has conducted extensive R&D activities over the past few years that have resulted in a sharp increase of biologic compounds that now account for about a quarter of its pipeline. Novartis hopes to use this strategic agreement to further grow its biologics unit.

According to Novartis, the partnership with Lonza offers an ideal platform for rapid development and production of innovative biological medicines. This could include monoclonal antibodies for treating diseases such as rheumatoid arthritis and cancer.

Mark Levick, global head of Novartis biologics, said that the strategic alliance with Lonza is a 'win-win' situation for both companies.

"It gives Novartis access to the most advanced technology and processes available to develop new biological medicines faster for the benefit of patients. At the same time, it allows Novartis to delay investments into manufacturing," said Levick.

Under the partnership, each project will have specific goals and Novartis can choose to transfer the commercial manufacturing in-house, following successful development of a compound. In the short-term, Novartis will gain access to extra manufacturing capacity.

11th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics